AVCT.F Stock Overview
Develops cancer drugs and in vitro diagnostics in the United Kingdom, France, North America, South Korea, rest of Europe, and internationally.
| Snowflake Score | |
|---|---|
| Valuation | 1/6 |
| Future Growth | 1/6 |
| Past Performance | 0/6 |
| Financial Health | 3/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
Avacta Group Plc Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | UK£0.55 |
| 52 Week High | UK£2.17 |
| 52 Week Low | UK£0.48 |
| Beta | 1.17 |
| 11 Month Change | -7.66% |
| 3 Month Change | -16.58% |
| 1 Year Change | -63.29% |
| 33 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | -61.92% |
Recent News & Updates
Recent updates
Shareholder Returns
| AVCT.F | US Biotechs | US Market | |
|---|---|---|---|
| 7D | 0% | 1.0% | -0.2% |
| 1Y | -63.3% | 10.7% | 22.9% |
Return vs Industry: AVCT.F underperformed the US Biotechs industry which returned 12% over the past year.
Return vs Market: AVCT.F underperformed the US Market which returned 24.2% over the past year.
Price Volatility
| AVCT.F volatility | |
|---|---|
| AVCT.F Average Weekly Movement | n/a |
| Biotechs Industry Average Movement | 10.3% |
| Market Average Movement | 5.7% |
| 10% most volatile stocks in US Market | 15.3% |
| 10% least volatile stocks in US Market | 2.9% |
Stable Share Price: AVCT.F has not had significant price volatility in the past 3 months.
Volatility Over Time: Insufficient data to determine AVCT.F's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2003 | 154 | Chris Coughlin | www.avacta.com |
Avacta Group Plc develops cancer drugs and in vitro diagnostics in the United Kingdom, France, North America, South Korea, rest of Europe, and internationally. The company operates through Diagnostics and Therapeutics segments. It provides its proprietary Affimer and pre|CISION technology platforms, which is used to deliver a portfolio of differentiated th therapeutic and diagnostic products that addresses various markets.
Avacta Group Plc Fundamentals Summary
| AVCT.F fundamental statistics | |
|---|---|
| Market cap | US$194.36m |
| Earnings (TTM) | -US$31.62m |
| Revenue (TTM) | US$29.46m |
6.9x
P/S Ratio-6.4x
P/E RatioIs AVCT.F overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| AVCT.F income statement (TTM) | |
|---|---|
| Revenue | UK£23.25m |
| Cost of Revenue | UK£12.00m |
| Gross Profit | UK£11.24m |
| Other Expenses | UK£36.19m |
| Earnings | -UK£24.95m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.07 |
| Gross Margin | 48.37% |
| Net Profit Margin | -107.31% |
| Debt/Equity Ratio | 159.6% |
How did AVCT.F perform over the long term?
See historical performance and comparison